Proteus Biomedical Inc.
This article was originally published in Start Up
Proteus Biomedical Inc. is developing a suite of proprietary MEMS-based technologies for congestive heart failure. It is staking its first claim in the fast-growing cardiac resynchronization therapy market.
You may also be interested in...
Welcome to “The Pink Sheet” DAILY’s round-up of news and notes from the first full day of the 2014 J.P. Morgan health care conference, including chats with the CEOs of Elcelyx Therapeutics and Arecor, news from Juno Therapeutics and Galena Biopharma, and more.
This is the device industry's wireless wake-up call. With all the speed and acceleration of an advancing information technology industry, forces outside of the medical device industry are driving shifts in medical product markets and business models. Those forces include the consumerization. globalization, systematization, and economies of scale created by IT. Wireless medicine enables connectivity between caregivers and patients, continuous monitoring of patients with chronic diseases, and a new paradigm for personalized medicine, one based on the patterns that can be gleaned from enormous volumes of individualized patient data, rather than on blood-based biomarkers.
Atrial fibrillation is the hottest sector among five highly dynamic areas within cardiovascular technology, according to an analysis by cvPipeline.